1. Home
  2. APRE vs VS Comparison

APRE vs VS Comparison

Compare APRE & VS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.63

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Logo Versus Systems Inc.

VS

Versus Systems Inc.

HOLD

Current Price

$1.39

Market Cap

9.3M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
APRE
VS
Founded
2006
2013
Country
United States
United States
Employees
N/A
5
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
9.3M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
APRE
VS
Price
$0.63
$1.39
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.10
N/A
AVG Volume (30 Days)
57.0K
58.8K
Earning Date
05-13-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
21.22
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.75
52 Week High
$1.93
$2.72

Technical Indicators

Market Signals
Indicator
APRE
VS
Relative Strength Index (RSI) 40.85 46.35
Support Level $0.57 $1.17
Resistance Level $0.83 $1.78
Average True Range (ATR) 0.06 0.15
MACD -0.01 -0.02
Stochastic Oscillator 34.44 6.16

Price Performance

Historical Comparison
APRE
VS

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

About VS Versus Systems Inc.

Versus Systems Inc operates within the technology sector, focusing on engagement-enhancing solutions through its proprietary prizing and promotions platform. This technology enables developers and content creators across streaming, live events, broadcast, gaming, and other media to integrate real-world prizes into their experiences, fostering greater consumer interaction and providing a compelling opportunity for brand partners and advertisers. The company operates in Canada and the USA.

Share on Social Networks: